Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy
A Lusa, C Alvarez, S Saxena Beem, TA Schwartz… - BMC rheumatology, 2022 - Springer
Abstract Introduction Immune checkpoint inhibitors (ICIs) enhance the immune system's
ability to target and destroy cancer cells, but this non-specific immune overactivation can …
ability to target and destroy cancer cells, but this non-specific immune overactivation can …
A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma
RR Munhoz, G Nader‐Marta, VP de Camargo… - Cancer, 2022 - Wiley Online Library
Background Cutaneous squamous‐cell carcinoma (CSCC) is among the most frequent
malignancies worldwide. For those not amenable to treatment with curative intent, immune …
malignancies worldwide. For those not amenable to treatment with curative intent, immune …
Neoadjuvant immunotherapy for hepatocellular carcinoma
TU Marron, M Schwartz, V Corbett… - Journal of Hepatocellular …, 2022 - Taylor & Francis
The treatment paradigm for hepatocellular carcinoma (HCC) had been stagnant until
recently, with new combinations of targeted and immunotherapies entering the first-and …
recently, with new combinations of targeted and immunotherapies entering the first-and …
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
E Mulder, K De Joode, S Litière, AJ Ten Tije… - BMC cancer, 2021 - Springer
Background The introduction of programmed cell death protein 1 (PD-1) blockers (ie
nivolumab and pembrolizumab) has significantly improved the prognosis of patients with …
nivolumab and pembrolizumab) has significantly improved the prognosis of patients with …
Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b)
L Zhou, J Yang, K Zhang, T Wang… - Journal of Medicinal …, 2024 - ACS Publications
Casitas B cell lymphoma-b (Cbl-b) is a vital negative regulator of TCR and BCR signaling
pathways, playing a significant role in setting an appropriate threshold for the activation of T …
pathways, playing a significant role in setting an appropriate threshold for the activation of T …
Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis
PURPOSE Many immune checkpoint inhibitors (ICIs) have been approved on the basis of
tumor response end points in nonrandomized trials, including objective response rate (ORR) …
tumor response end points in nonrandomized trials, including objective response rate (ORR) …
Imaging of tumour response to immunotherapy
A wide range of cancer immunotherapy approaches has been developed including non-
specific immune-stimulants such as cytokines, cancer vaccines, immune checkpoint …
specific immune-stimulants such as cytokines, cancer vaccines, immune checkpoint …
Long‐term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors
A Rogiers, A Boekhout, JK Schwarze… - Journal of …, 2019 - Wiley Online Library
Immune checkpoint inhibitors have become a standard of care option for the treatment of
patients with advanced melanoma. Since the approval of the first immune checkpoint (CTLA …
patients with advanced melanoma. Since the approval of the first immune checkpoint (CTLA …
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
Increasing evidence suggests that some immunotherapy dosing regimens for patients with
advanced cancer could result in overtreatment. Given the high costs of these agents, and …
advanced cancer could result in overtreatment. Given the high costs of these agents, and …
Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice
Abstract Background and Aims Immunotherapy with programmed cell death 1 (PD‐
1)/programmed death ligand 1 (PD‐L1) blockade has shown low response rates in liver …
1)/programmed death ligand 1 (PD‐L1) blockade has shown low response rates in liver …